Introduction
============

Condyloma acuminatum (CA) is a sexually transmitted disease that manifests as epidermal wart-like hyperplasia caused by human papilloma virus (HPV). The incidence rate of CA is only secondary to gonorrhea, and CA is generally characterized by strong infectivity and high recurrence rate ([@b1-etm-0-0-4445]). Clinical treatment methods include chemotherapy, physiotherapy, immunotherapy and photodynamic therapy. Among them, physiotherapeutic methods, such as high-frequency fulguration and CO~2~ laser therapy, have various advantages such as rapid clearance of warts, high safety and low cost, although the recurrence rate of CA is relatively high ([@b2-etm-0-0-4445],[@b3-etm-0-0-4445]). Decreased immune functions of cells surrounding warts, and subclinical infection are major factors contributing to recurrence ([@b4-etm-0-0-4445]). Although Bacillus Calmette-Guérin polysaccharide nucleic acid (BCG-PSN) can serve as an efficient two-sided immune regulator, it is limited in clinical application because of the requirement for cold preservation and aggravated pain from intramuscular injection ([@b5-etm-0-0-4445]). Topical 5% imiquimod cream is a new form of immune regulator that is convenient and safe for application ([@b6-etm-0-0-4445]). In this study, we aimed to analyze the clinical efficacy of high-frequency fulguration combined with 5% imiquimod cream for the treatment of CA, and determine the effect of this treatment on the immune functions of T cells, and serum levels of interleukin (IL)-2 and IL-10.

Patients and methods
====================

### Patients

We consecutively selected 112 patients who were diagnosed with CA in Guangzhou Institute of Dermatology between January 2014 and January 2016. This study was approved by the Ethics Committee of Guangzhou Medical University. Signed written informed consents were obtained from the patients and/or guardians before the study. The inclusion criteria were as follows: i) patients who met the diagnostic criteria of CA, typical clinical manifestations + positive result in acetowhitening test + positive result in HPV immune colloidal gold test; ii) patients with good tolerance for treatment, complete medical history, and who signed the written informed consent. Exclusion criteria were as follows: i) patients who were in the gestation or lactation period; ii) patients with autoimmune diseases, or those who took immunosuppressors or glucocorticoid drugs within two weeks of examination; iii) patients who were allergic to BCG-PSN or imiquimod cream; and iv) patients who were complicated with other underlying diseases, such as dysfunctions of the heart, liver, lung, kidney or brain.

According to order of hospitalization, the patients were randomly divided into the observation group (n=56) and control group (n=56). Baseline parameters of patients in both groups were comparable ([Table I](#tI-etm-0-0-4445){ref-type="table"}).

### Research methods

Patients in the control group received high-frequency fulguration and intramuscular injection of BCG-PSN. For high-frequency fulguration, a GX-III Type Series Multi-Purpose Electric Ion Operating Apparatus (Nanning Kelun New Technology Co., Ltd., Guangxi, China) was applied as follows: after standard disinfection and topical anesthesia, the metal contactor was moved from the inner part to the outer part of the skin lesion for fulguration; the range of fulguration was set as 0.5 cm of the diameter of warts, and the contactor could reach the upper dermis; regular anti-infection procedures were applied; after 1 week, patients received intramuscular injections (1 ml) of BCG-PSN (Disu, approved no. S19983036, 1 ml/bottle; Zhejiang Wanma Pharmaceutical Co., Ltd., Zhejiang, China), 3 times/week; the treatment course lasted for 12 weeks.

Patients in the observation group received the combination therapy of high-frequency fulguration and external application of 5% imiquimod cream. The fulguration procedures were the same as in the control group. Imiquimod cream (Likejie, approved no. H20030129, 3 g:150 mg; Hubei Keyi Pharmaceutical Co., Ltd., Hubei, China) was applied before sleep 3 times/week, and lesions were rinsed using water the next morning; the treatment course lasted for 12 weeks.

### Observational indexes

During the 6-month follow-up, we compared the clinical effective rate and recurrence rate between the two groups. The evaluation criteria of clinical effectiveness were as follows: completely cured, recovered, effective and non-effective. Completely cured was characterized by normal skin mucosa, negative result in acetowhitening test, complete remission of warts, and no recurrence in 6 months; recovered was characterized by fundamentally normal skin mucosa, positive result in acetowhitening test, 80% remission of warts, and no aggravation or recurrence in 6 months; effective referred to significant recovery in skin mucosa, positive result in acetowhitening test, 50--79% remission of warts, and no aggravation or recurrence in 6 months; non-effective referred to no changes or aggravation in clinical symptoms and vital signs, and positive result in acetowhitening test. Recurrence referred to the emergence of newly-developed warts at the original wart site or within 2.0 cm area of the original wart site in 6 months, and positive result in acetowhitening test with exclusion of repeated history of infection. Total effective rate = (completely cured cases + recovered cases + effective cases)/total cases × 100%; effective degree referred to the relative ratios of completely cured cases, recovered cases and effective cases; recurrence rate = cases of recurrence/total effective cases × 100%.

We compared the immune functions of T cells, and the serum levels of IL-2 and IL-10 of patients in both groups. A total of 6 ml of fasting elbow venous blood was collected from patients in the morning, and the samples were centrifuged at 2,500 × g for 20 min. The upper serum layer was preserved at −70°C. The levels of IL-2 and IL-10 were measured by enzyme-linked immunosorbent assay (ELISA) (KeyGen, Nanjing, China) according to the manufacturer\'s instructions. Reagents were purchased from Beyotime Institute of Biotechnology (Jiangsu, China). Measurement was repeated three times, and data were averaged. The cells were placed in lymphocyte separation medium, followed by density gradient centrifugation for the isolation of cells. FACSCaliber flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA) was applied for the detection of CD3^+^, CD4^+^ and CD8^+^ cells, and the percentage of CD4^+^/CD8^+^.

### Statistical analysis

SPSS 20.0 statistical software (SPSS, Inc., Chicago, IL, USA) was applied for statistical analysis. Numerical data are presented as mean ± standard deviation (SD), independent sample t-test was applied for intergroup comparisons, and paired t-test was applied for intragroup comparisons. Categorical data are presented as cases or ratio (%), and Chi-square test or Fisher\'s exact probability test was applied for intergroup comparisons. Rank-sum test was applied for the comparison of ranked data. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical effective rate and recurrence rate

The total effective rate in the observation group was higher than that in the control group (p\<0.05), but no significant differences were identified in comparisons of the effective and recurrence rate between the two groups (p\>0.05; [Table II](#tII-etm-0-0-4445){ref-type="table"}).

### Immune functions of T cells

After treatment, the levels of CD3^+^ and CD4^+^ cells, and the CD4^+^/CD8^+^ ratio in both groups were increased compared with the levels before treatment (p\<0.05). There was no significant difference in the levels of CD8^+^ cells in either group before and after treatment (p\>0.05). There was no significant difference in the comparison of T cells before and after treatment between the groups (p\>0.05; [Table III](#tIII-etm-0-0-4445){ref-type="table"}).

### Serum levels of IL-2 and IL-10

In both groups, the serum levels of IL-2 were increased and the levels of IL-10 were decreased after treatment, compared with the levels before treatment. This improvement was superior in the observation group compared with the control group (p\<0.05; [Table IV](#tIV-etm-0-0-4445){ref-type="table"}).

Discussion
==========

CA is characterized by a relatively long latency period, few obvious manifestations in the early period, and a wide range of contagions. Photodynamic treatment of CA in the urethral orifice of male patients can achieve good efficacy, but cannot be promoted in clinical practice because of high medical costs ([@b7-etm-0-0-4445]). Therefore, high-frequency fulguration combined with immune enhancing therapy has currently become the major treatment method. In this study, we employed high-frequency fulguration combined with immune enhancing therapy, although high-frequency fulguration cannot effectively eliminate residual HPV surrounding warts. These HPVs were primarily distributed within the range of 1.0--2.0 cm away from the center of warts, which resulted in HPV being the main pathogen ([@b8-etm-0-0-4445]). Previous studies ([@b9-etm-0-0-4445],[@b10-etm-0-0-4445]) have confirmed that imiquimod cream, with no antiviral effect, can promote peripheral monocytes and keratinocyte to express and secrete multiple cytokines, such as interferon-γ (INF-γ), IL-2 and IL-12, thus enhancing the immune functions of B lymphocytes and T lymphocytes. Regarding the Th1 cellular immunity in HPV infection, imiquimod cream can thoroughly eliminate the viral infection, resulting in clinical cure. BCG-PSN is also an efficient two-sided immune regulator. In this study, we found that the total effective rate in the observation group was higher than that in the control group, but no significant differences were identified in the comparisons of the effective degree and recurrence rate between the two groups. A previous study ([@b11-etm-0-0-4445]) reported that compared with healthy subjects, the levels of CD3^+^ and CD4^+^ cells in peripheral blood of patients with CA are lower, the levels of CD8^+^ cells are elevated, and the CD4^+^/CD8^+^ ratio is significantly decreased. Compared with the levels before treatment, the levels of CD3^+^ and CD4^+^ cells, and the percentage of CD4^+^/CD8^+^ were increased after treatment, but no changes were observed in the levels of CD8^+^ cells. In addition, there were no significant differences in the comparison of T cells before and after treatment between the two groups. These results demonstrated the equivalent efficiency of the drugs for enhancing the immune response to cytotoxicity. In both groups, the serum levels of IL-2 were increased after treatment compared with those before treatment, and the levels of IL-10 were decreased. The improvement in patients of the observation group was superior to that of the control group. This suggested that imiquimod cream may excel in enhancing the functions of cytokines. IL-2, also known as a T cell growth factor, is generally produced by activated CD4^+^ and CD8^+^ T cells, and has a wide range of biological activities ([@b12-etm-0-0-4445],[@b13-etm-0-0-4445]). However, IL-10, a multifunctional negative regulator, is mainly involved in autoimmune diseases, infectious diseases, tumors and transplantation immunity ([@b14-etm-0-0-4445],[@b15-etm-0-0-4445]).

Imiquimod cream is an artificially synthesized non-nucleoside heterocyclic amine drug. It is characterized by relatively minor local responses compared with BCG-PSN, such as local erythema and mild erosion. Patients can frequently tolerate these symptoms, which are important factors affecting the efficacy of treatment ([@b16-etm-0-0-4445]). However, single administration of immunopotentiators may result in delays of treatment because the onset time of imiquimod cream is 4--12 weeks, which is insufficient for treatment ([@b17-etm-0-0-4445]). In conclusion, good clinical efficacy for the treatment of CA can be achieved via the combination of high-frequency fulguration and 5% imiquimod cream, and is correlated with enhanced immune functions of T cells, and improvement in the serum levels of IL-2 and IL-10. Therefore, this treatment method is worthy of being promoted in clinical practice.
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###### 

Comparison of baseline parameters between the two groups.

  Groups                         Control (n=56)   Observation (n=56)   t/χ^2^ test   P-value
  ------------------------------ ---------------- -------------------- ------------- ---------
  Male/female                    32/24            35/21                0.334         0.563
  Age (years)                    41.2±6.9         39.8±5.7             0.252         0.687
  Disease course (days)          21.5±7.3         22.6±7.8             0.196         0.859
  Location of skin lesion                                              0.944         0.624
  Penis                          28               33                                 
  Perineum                       15               13                                 
  Crissum                        13               10                                 
  Shape of wart                                                        0.207         0.902
  Papulous-shaped                15               13                                 
  Cauliflower-shaped             30               32                                 
  Papilloma-shaped               11               11                                 
  Diameter of skin lesion (cm)   1.1±0.4          1.2±0.5              0.096         0.925
  Number of skin lesion          4.3±1.2          4.6±1.5              0.152         0.868
  Initial onset                  48               47                   0.069         0.792
  Recurrence                     8                9                                  

###### 

Clinical effective rate and recurrence rate (cases, %).

  Groups               Completely cured   Recovered   Effective   Non-effective   Effective rate   Recurrence rate
  -------------------- ------------------ ----------- ----------- --------------- ---------------- -----------------
  Control (n=56)       25                 7           8           16              40 (71.4)        4 (10.0)
  Observation (n=56)   32                 10          7           7               49 (87.5)        3 (6.1)
  Z/χ^2^ test                             −1.858                  4.432           --               
  P-value                                 0.063                   0.035           0.696            

###### 

Percentage of T cell (%).

                CD3^+^     CD4^+^                                                   CD8^+^     CD4^+^/CD8^+^                                                                             
  ------------- ---------- -------------------------------------------------------- ---------- -------------------------------------------------------- ---------- ---------- ---------- ----------------------------------------------------------
  Control       35.9±6.2   38.6±6.6^[a](#tfn1-etm-0-0-4445){ref-type="table-fn"}^   29.8±5.4   33.6±6.2^[a](#tfn1-etm-0-0-4445){ref-type="table-fn"}^   32.4±6.2   32.8±6.4   92.5±8.2   105.5±11.2^[a](#tfn1-etm-0-0-4445){ref-type="table-fn"}^
  Observation   34.3±6.4   38.5±6.7^[a](#tfn1-etm-0-0-4445){ref-type="table-fn"}^   28.7±5.3   33.3±6.4^[a](#tfn1-etm-0-0-4445){ref-type="table-fn"}^   31.6±6.3   32.4±6.6   93.1±8.3   104.7±12.3^[a](#tfn1-etm-0-0-4445){ref-type="table-fn"}^
  t-test        0.152      0.096                                                    0.232      0.078                                                    0.312      0.102      0.352      0.152
  P-value       0.896      0.935                                                    0.852      0.924                                                    0.789      0.936      0.724      0.968

p\<0.05, comparison of the levels before and after treatment.

###### 

Serum levels of IL-2 and IL-10 (µg/l).

                IL-2         IL-10                                                                  
  ------------- ------------ ---------------------------------------------------------- ----------- ---------------------------------------------------------
  Control       112.3±45.5   154.8±52.3^[a](#tfn2-etm-0-0-4445){ref-type="table-fn"}^   65.3±23.2   58.7±21.2^[a](#tfn2-etm-0-0-4445){ref-type="table-fn"}^
  Observation   105.6±46.8   198.3±57.9^[a](#tfn2-etm-0-0-4445){ref-type="table-fn"}^   66.8±25.4   51.2±22.7^[a](#tfn2-etm-0-0-4445){ref-type="table-fn"}^
  t-test        0.213        9.524                                                      0.154       7.523
  P-value       0.865        0.001                                                      0.968       0.001

p\<0.05, comparison of the levels before and after treatment. IL, interleukin.
